Pharmaceuticals, Biotechnology and Life Sciences
Faron Pharma posted operating loss of €6.3 million for the six months ended 30 June 2019, cutting it from the same period last year, of €14.0 million.
Faron Pharmaceuticals has received Fast Track designation from the US Food and Drug Administration (FDA) for Traumakine, which also has…
Faron Pharmaceuticals has appointed Dr. Juhana Heinonen as Chief Commercial Officer to join the company in January 2018.
Finish patent office has accepts Faron’s new formulation for a respiratory orphan disease ARDS
Faron Pharmaceuticals Oy (Faron), the clinical stage biopharmaceutical company, has started dealing its Ordinary Shares on the AIM market of the London Stock Exchange with effect from 8.00 a.m. Tuesday after placing and subscription for 3,846,154 new Ordinary Shares, raising £10.0 million at a price of 260p per ordinary.